These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 26254023)

  • 1. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
    Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.
    Goh G; Schmid R; Guiver K; Arpornwirat W; Chitapanarux I; Ganju V; Im SA; Kim SB; Dechaphunkul A; Maneechavakajorn J; Spector N; Yau T; Afrit M; Ahmed SB; Johnston SR; Gibson N; Uttenreuther-Fischer M; Herrero J; Swanton C
    PLoS Med; 2016 Dec; 13(12):e1002136. PubMed ID: 27923043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
    Harbeck N; Huang CS; Hurvitz S; Yeh DC; Shao Z; Im SA; Jung KH; Shen K; Ro J; Jassem J; Zhang Q; Im YH; Wojtukiewicz M; Sun Q; Chen SC; Goeldner RG; Uttenreuther-Fischer M; Xu B; Piccart-Gebhart M;
    Lancet Oncol; 2016 Mar; 17(3):357-366. PubMed ID: 26822398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
    Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
    Gordon MS; Springett GM; Su YB; Ould-Kaci M; Wind S; Zhao Y; LoRusso PM
    Future Oncol; 2015; 11(10):1479-91. PubMed ID: 25963426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
    Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
    Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
    Bartsch V
    Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.
    Bahleda R; Varga A; Bergé Y; Soria JC; Schnell D; Tschoepe I; Uttenreuther-Fischer M; Delord JP
    Br J Cancer; 2018 Feb; 118(3):344-352. PubMed ID: 29337963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
    Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
    Vermorken JB; Rottey S; Ehrnrooth E; Pelling K; Lahogue A; Wind S; Machiels JP
    Ann Oncol; 2013 May; 24(5):1392-400. PubMed ID: 23293114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UFT/leucovorin plus vinorelbine combination for advanced breast cancer.
    Fumoleau P; Déporte R; Kerbrat P; Bonneterre J; Fargeot P
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):50-5. PubMed ID: 11098494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
    Thallinger C; Lang I; Kuhar CG; Bartsch R; Singer CF; Petruzelka L; Melichar B; Knittelfelder R; Brodowicz T; Zielinski C
    BMC Cancer; 2016 Feb; 16():121. PubMed ID: 26887956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.